Study of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-ALL Patients
The purpose of this study is to evaluate the efficacy and safety of venetoclax combined with azacitidine regimen for newly diagnosed T-ALL patients.
T-cell Acute Lymphoblastic Leukemia|Recruiting
DRUG: Venetoclax, Azacitidine
Overall Response Rate (ORR), The overall response (complete remission, complete remission with incomplete blood count recovery) rate achieved after one or two courses (21 days) induction therapy by venetoclax combined azacitidine regimen., At the end of Cycle 1 (each cycle is 21 days)
Overall survial (OS), It is measured from the date of entry into this trial to the date of death from any cause; patients not known to have died at last follow-up are censored on the date they were last known to be alive., 2 years|Progression-Free Survival (PFS), It is measured from the date of entry into this trial to the date of progression or death., 2 years|Number of adverse events, Adverse events are evaluated with CTCAE V5.0., 2 years
This is a phase 2, open Label, single arm, multi-center study for newly diagnosed T-cell acute lymphoblastic leukemia patients. The patients will receive vanetoclax combined with azacitidine as the induction regimen.